Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept SC plus methotrexate versus methotrexate alone in early methotrexate-naive rheumatoid arthritis
2015-001275-50Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Abatacept + methotrexate with Methotrexate monotherapy (2 arms). Primary endpoint: SDAI remission at Week 24. Started Sep 2015; status: completed.
02
Drugs
abataceptmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-001275-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001275-50.